drugset / Trial / NCT02350712
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test a study drug called patritumab. Patritumab may work when combined with other medications that are approved in the UK for treating Squamous Cell Carcinoma of the Head and Neck (SCCHN), called cetuximab, cisplatin or carboplatin. It is hoped that patritumab may have some benefit in treating patients with cancer. This study will help identify how much patritumab can be given in combination with cetuximab, and cisplatin or carboplatin. This study will show how safe and how well tolerated patritumab is when these medications are given together.
Timeline
- Start
- 2014-12
- Primary completion
- 2016-03
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Patritumab | Monoclonal antibody | 9 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |